Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Vasculitis-Pipeline Review, H1 2015

Vasculitis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Vasculitis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Vasculitis-Pipeline Review, H1 2015', provides an overview of the Vasculitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Vasculitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Vasculitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Vasculitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Vasculitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Vasculitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Vasculitis Overview 8

Therapeutics Development 9

Pipeline Products for Vasculitis-Overview 9

Pipeline Products for Vasculitis-Comparative Analysis 10

Vasculitis-Therapeutics under Development by Companies 11

Vasculitis-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Vasculitis-Products under Development by Companies 16

Vasculitis-Companies Involved in Therapeutics Development 18

AnGes MG, Inc. 18

Anthera Pharmaceuticals Inc. 19

Aprogen, Inc. 20

ChemoCentryx, Inc. 21

Clearside BioMedical, Inc. 22

Epirus Biopharmaceuticals, Inc. 23

F. Hoffmann-La Roche Ltd. 24

GlaxoSmithKline plc 25

Hemostemix Ltd 26

Hospira, Inc. 27

K-Stemcell Co., Ltd. 28

Panacea Biotec Limited 29

Pluristem Therapeutics Inc. 30

Sandoz Inc. 31

XOMA Corporation 32

Vasculitis-Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Target 34

Assessment by Mechanism of Action 36

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Drug Profiles 42

ACP-01-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

belimumab-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

beperminogene perplasmid-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

blisibimod-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

CCX-168-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

gevokizumab-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

rituximab biosimilar-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

rituximab biosimilar-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

rituximab biosimilar-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

rituximab biosimilar-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

rituximab biosimilar-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

rituximab biosimilar-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

tocilizumab-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

triamcinolone acetonide-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Vascostem-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Vasculitis-Recent Pipeline Updates 72

Vasculitis-Dormant Projects 98

Vasculitis-Product Development Milestones 99

Featured News & Press Releases 99

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 99

Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 99

Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis 100

Jan 10, 2013: Clearside Biomedical Announces Plans For Clinical Testing Of CLS1001 Suprachoroidal Injectable Suspension For Treatment Of Some Eye Diseases 100

Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal 100

Aug 16, 2012: Pluristem Receives Approval From Indian Ministry Of Health For Use Of PLX Cells In Phase II Trial For Treatment Of Buerger's Disease 101

May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress 101

Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis 102

Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology 103

Appendix 104

Methodology 104

Coverage 104

Secondary Research 104

Primary Research 104

Expert Panel Validation 104

Contact Us 104

Disclaimer 105

List of Tables

Number of Products under Development for Vasculitis, H1 2015 9

Number of Products under Development for Vasculitis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Development by Companies, H1 2015 (Contd..1) 17

Vasculitis-Pipeline by AnGes MG, Inc., H1 2015 18

Vasculitis-Pipeline by Anthera Pharmaceuticals Inc., H1 2015 19

Vasculitis-Pipeline by Aprogen, Inc., H1 2015 20

Vasculitis-Pipeline by ChemoCentryx, Inc., H1 2015 21

Vasculitis-Pipeline by Clearside BioMedical, Inc., H1 2015 22

Vasculitis-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 23

Vasculitis-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 24

Vasculitis-Pipeline by GlaxoSmithKline plc, H1 2015 25

Vasculitis-Pipeline by Hemostemix Ltd, H1 2015 26

Vasculitis-Pipeline by Hospira, Inc., H1 2015 27

Vasculitis-Pipeline by K-Stemcell Co., Ltd., H1 2015 28

Vasculitis-Pipeline by Panacea Biotec Limited, H1 2015 29

Vasculitis-Pipeline by Pluristem Therapeutics Inc., H1 2015 30

Vasculitis-Pipeline by Sandoz Inc., H1 2015 31

Vasculitis-Pipeline by XOMA Corporation, H1 2015 32

Assessment by Monotherapy Products, H1 2015 33

Number of Products by Stage and Target, H1 2015 35

Number of Products by Stage and Mechanism of Action, H1 2015 37

Number of Products by Stage and Route of Administration, H1 2015 39

Number of Products by Stage and Molecule Type, H1 2015 41

Vasculitis Therapeutics-Recent Pipeline Updates, H1 2015 72

Vasculitis-Dormant Projects, H1 2015 98

List of Figures

Number of Products under Development for Vasculitis, H1 2015 9

Number of Products under Development for Vasculitis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 33

Number of Products by Top 10 Targets, H1 2015 34

Number of Products by Stage and Top 10 Targets, H1 2015 34

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 36

Number of Products by Top 10 Routes of Administration, H1 2015 38

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 38

Number of Products by Top 10 Molecule Types, H1 2015 40

Number of Products by Stage and Top 10 Molecule Types, H1 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AnGes MG, Inc.

Anthera Pharmaceuticals Inc.

Aprogen, Inc.

ChemoCentryx, Inc.

Clearside BioMedical, Inc.

Epirus Biopharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

Hemostemix Ltd

Hospira, Inc.

K-Stemcell Co., Ltd.

Panacea Biotec Limited

Pluristem Therapeutics Inc.

Sandoz Inc.

XOMA Corporation

Vasculitis Therapeutic Products under Development, Key Players in Vasculitis Therapeutics, Vasculitis Pipeline Overview, Vasculitis Pipeline, Vasculitis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com